Shanghai Haoyuan Chemexpress (SHSE:688131) Has A Somewhat Strained Balance Sheet
Jun 13
Chinese (SSE) Life Sciences Industry Analysis
UpdatedJun 16, 2024
DataAggregated Company Financials
Companies24
- 7D1.9%
- 3M-15.1%
- 1Y-37.7%
- YTD-31.6%
In the last week, the Life Sciences industry is up 1.9%, with WuXi AppTec up 3.1%. Meanwhile, Hangzhou Tigermed Consulting actually underperformed within the industry, shrinking 5.7% in the last week. In the past year, the industry is down 38%. Looking forward, earnings are forecast to grow by 29% annually.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Jun 2024 | CN¥308.1b | CN¥88.3b | CN¥13.4b | 27.3x | 23x | 3.5x |
| Tue, 14 May 2024 | CN¥337.4b | CN¥88.3b | CN¥13.3b | 29.5x | 25.3x | 3.8x |
| Thu, 11 Apr 2024 | CN¥335.6b | CN¥90.3b | CN¥15.0b | 33.1x | 22.4x | 3.7x |
| Sat, 09 Mar 2024 | CN¥346.8b | CN¥90.5b | CN¥15.5b | 32.4x | 22.4x | 3.8x |
| Mon, 05 Feb 2024 | CN¥325.7b | CN¥91.1b | CN¥16.1b | 29.5x | 20.3x | 3.6x |
| Wed, 03 Jan 2024 | CN¥463.2b | CN¥91.1b | CN¥16.1b | 38.7x | 28.8x | 5.1x |
| Fri, 01 Dec 2023 | CN¥531.6b | CN¥91.1b | CN¥16.1b | 38.5x | 33.1x | 5.8x |
| Sun, 29 Oct 2023 | CN¥529.7b | CN¥91.7b | CN¥18.3b | 35.8x | 28.9x | 5.8x |
| Tue, 26 Sep 2023 | CN¥498.2b | CN¥92.0b | CN¥18.3b | 33.8x | 27.2x | 5.4x |
| Thu, 24 Aug 2023 | CN¥471.4b | CN¥91.6b | CN¥18.6b | 33x | 25.4x | 5.1x |
| Sat, 22 Jul 2023 | CN¥462.1b | CN¥91.3b | CN¥18.5b | 34.9x | 25x | 5.1x |
| Mon, 19 Jun 2023 | CN¥501.6b | CN¥91.3b | CN¥18.5b | 37.7x | 27.2x | 5.5x |
| Wed, 17 May 2023 | CN¥511.1b | CN¥91.3b | CN¥18.4b | 40.5x | 27.8x | 5.6x |
| Fri, 14 Apr 2023 | CN¥613.6b | CN¥91.2b | CN¥19.1b | 54x | 32.1x | 6.7x |
| Sun, 12 Mar 2023 | CN¥594.6b | CN¥85.5b | CN¥20.0b | 50.9x | 29.8x | 7x |
| Tue, 07 Feb 2023 | CN¥664.0b | CN¥86.6b | CN¥20.8b | 57.3x | 31.9x | 7.7x |
| Thu, 05 Jan 2023 | CN¥620.2b | CN¥86.6b | CN¥20.8b | 53.7x | 29.8x | 7.2x |
| Sat, 03 Dec 2022 | CN¥594.2b | CN¥86.6b | CN¥20.8b | 50.4x | 28.6x | 6.9x |
| Mon, 31 Oct 2022 | CN¥569.2b | CN¥85.8b | CN¥20.7b | 44x | 27.5x | 6.6x |
| Wed, 28 Sep 2022 | CN¥551.3b | CN¥78.2b | CN¥16.9b | 47x | 32.6x | 7x |
| Fri, 26 Aug 2022 | CN¥601.0b | CN¥73.5b | CN¥17.2b | 58.3x | 35x | 8.2x |
| Sun, 24 Jul 2022 | CN¥678.3b | CN¥69.0b | CN¥15.2b | 69.6x | 44.7x | 9.8x |
| Tue, 21 Jun 2022 | CN¥641.2b | CN¥69.0b | CN¥15.2b | 63x | 42.2x | 9.3x |
| Thu, 19 May 2022 | CN¥589.2b | CN¥68.5b | CN¥15.1b | 53.9x | 38.9x | 8.6x |
| Sat, 16 Apr 2022 | CN¥651.7b | CN¥62.7b | CN¥15.0b | 63.3x | 43.5x | 10.4x |
| Mon, 14 Mar 2022 | CN¥603.8b | CN¥62.4b | CN¥14.9b | 63.3x | 40.4x | 9.7x |
| Wed, 09 Feb 2022 | CN¥587.5b | CN¥57.5b | CN¥12.3b | 66x | 47.7x | 10.2x |
| Fri, 07 Jan 2022 | CN¥681.7b | CN¥57.5b | CN¥12.3b | n/a | 55.4x | 11.9x |
| Sun, 05 Dec 2021 | CN¥854.3b | CN¥56.9b | CN¥12.1b | 97x | 70.3x | 15x |
| Tue, 02 Nov 2021 | CN¥841.8b | CN¥56.9b | CN¥12.2b | 96.6x | 69.2x | 14.8x |
| Thu, 30 Sep 2021 | CN¥980.5b | CN¥55.1b | CN¥12.7b | 105.8x | 76.9x | 17.8x |
| Sat, 28 Aug 2021 | CN¥873.1b | CN¥55.1b | CN¥12.7b | 97.9x | 68.5x | 15.8x |
| Sun, 04 Jul 2021 | CN¥984.9b | CN¥53.4b | CN¥11.5b | 101x | 85.6x | 18.5x |
Price to Earnings Ratio
85.6x
Current Industry PE
- Investors are pessimistic on the Chinese Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 23.0x which is lower than its 3-year average PE of 39.4x.
- The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 5.2% per year over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 0.061% | |
| Healthcare | -0.73% | |
| Life Sciences | 1.87% | |
| Clinical Research and Equipment | 1.87% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥43.70 | 3.1% +CN¥3.8b | -39.1% | PE13.6x | |
| 688114 MGI Tech | CN¥51.59 | 7.7% +CN¥1.5b | -41.2% | PS7.5x | |
| 300759 Pharmaron Beijing | CN¥20.13 | 3.0% +CN¥1.0b | -37.0% | PE24.2x | |
| 603108 Shanghai Runda Medical Technology | CN¥16.25 | 6.0% +CN¥550.9m | 5.7% | PE45.3x | |
| 688131 Shanghai Haoyuan Chemexpress | CN¥31.18 | 6.5% +CN¥285.7m | -48.7% | PE47.9x |
